APA (7th ed.) Citation

DY, R., HX, W., Y, X., PN, M., Y, D., G, R., . . . RH, X. (2025). Garsorasib, a KRAS G12C inhibitor, with or without cetuximab, an EGFR antibody, in colorectal cancer cohorts of a phase II trial in advanced solid tumors with KRAS G12C mutation. Signal transduction and targeted therapy, 10(1), 189. https://doi.org/10.1038/s41392-025-02274-z

Chicago Style (17th ed.) Citation

DY, Ruan, et al. "Garsorasib, a KRAS G12C Inhibitor, with or Without Cetuximab, an EGFR Antibody, in Colorectal Cancer Cohorts of a Phase II Trial in Advanced Solid Tumors with KRAS G12C Mutation." Signal Transduction and Targeted Therapy 10, no. 1 (2025): 189. https://doi.org/10.1038/s41392-025-02274-z.

MLA (9th ed.) Citation

DY, Ruan, et al. "Garsorasib, a KRAS G12C Inhibitor, with or Without Cetuximab, an EGFR Antibody, in Colorectal Cancer Cohorts of a Phase II Trial in Advanced Solid Tumors with KRAS G12C Mutation." Signal Transduction and Targeted Therapy, vol. 10, no. 1, 2025, p. 189, https://doi.org/10.1038/s41392-025-02274-z.